Full-Time

Senior Director

Legal

Posted on 9/24/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$227k - $296.5kAnnually

Senior

San Carlos, CA, USA

Category
Legal
Legal & Compliance
Requirements
  • Active licensure in good standing with the California Bar or eligibility to practice law as a registered in-house counsel in California
  • Comprehensive knowledge of laws implicated in the sale and promotion of pharmaceutical products
  • Complex contract drafting and negotiations skills
  • Excellent written and verbal communication skills
  • Ability to provide timely, practical, and actionable legal advice
  • High emotional intelligence, capable of collaboratively influencing decision-making through the respectful exchange of competing ideas and perspectives
  • Self-driven to identify and solve complex and challenging problems
  • 10+ years of legal practice in healthcare regulatory and pharmaceutical industry law, with experience in general corporate transactional and/or litigation matters
  • J.D. from a respected law school and strong academic credentials
Responsibilities
  • Legal advice related to pharmaceutical Sales and Promotion – Provide practical and timely advice, training and solutions regarding compliance with laws related to all aspects of U.S. and ex-U.S. pharmaceutical product sales and promotion, including fraud and abuse; interactions with healthcare professionals and patients; market access, reimbursement and government price reporting; channel distribution; pharmacy services; and data privacy
  • Compliance Policy Development and Training – Develop and implement policies, resources, and training to drive comprehensive, functional knowledge among product teams regarding business conduct in accordance with the law and ethical standards
  • Contract Drafting and Negotiations – Support negotiation of contractual arrangements encompassing a wide array of third parties, including healthcare providers and vendors of services, products and data, to ensure appropriate protection of Corcept’s business opportunities, assets, confidential information and intellectual property

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions. The goal of Corcept is to lead in cortisol modulation therapies and enhance the quality of life for patients suffering from disorders related to cortisol imbalance.

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in cortisol therapies boosts demand for Corcept's products.
  • Advancements in AI-driven drug discovery could accelerate Corcept's R&D processes.
  • Telemedicine expansion increases access to treatments like Korlym, broadening market reach.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market or regulatory changes.
  • Strategic shift to oncology may divert resources from core cortisol modulation focus.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE